Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.
Chan, B.K., Hanan, E.J., Bowman, K.K., Bryan, M.C., Burdick, D., Chan, E., Chen, Y., Clausen, S., Dela Vega, T., Dotson, J., Eigenbrot, C., Elliott, R.L., Heald, R.A., Jackson, P.S., Knight, J.D., La, H., Lainchbury, M.D., Malek, S., Purkey, H.E., Schaefer, G., Schmidt, S., Seward, E.M., Sideris, S., Shao, L., Wang, S., Yeap, S.K., Yen, I., Yu, C., Heffron, T.P.(2016) J Med Chem 59: 9080-9093
- PubMed: 27564586 
- DOI: 10.1021/acs.jmedchem.6b00995
- Primary Citation of Related Structures:  
5HCY, 5HCX, 5HCZ - PubMed Abstract: 
Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M) in the inhibitor binding site has be ...